Latest Headlines

Latest Headlines

Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine

Agenus and a Sanofi-NIH collaboration both gave updates on their genital herpes vaccine candidates this week. The Agenus vaccine, HerpV, is leading the race, having met its primary endpoint in a Phase II trial of 80 subjects, 70 of whom received the treatment.

Government shutdown effects on biomedical research outlined

The White House's Office of Management and Budget released a new report that sheds light on how the 16-day federal government shutdown in October impacted scientific research.

Fewer NIH grants affected by sequestration than initially projected

NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.

Continued NIH investment in NGS helps Illumina post big quarter

Over the past 12 months spending cuts at National Institutes of Health have raised doubts about its ability to continue increasing investment in next-generation sequencing at the rate seen in recent years. Yet this week brought two pieces of news that suggest NIH is backing more and more NGS projects.

IBM gets deeper into Big Data and EHRs with new projects

Having updated its disease-modeling platform last week, tech giant IBM has now snagged a grant to dig into electronic health records to predict heart disease and opened a Big Data research lab.

HIV trial follow-up quashes fears of infection risk

When NIH canned its HIV vaccine trial in April, the field, yet again, lost its brightest hope. Since then, NIH has continued to monitor participants in the trial, and this week it presented an update in the New England Journal of Medicine.

Amid shutdown, NIH forced to turn away new trial patients

Thanks to the government shutdown, about 73% of NIH staff have seen their jobs put on hold--and no staff means no new studies. As The Washington Post reports, the halt has forced researchers to turn away patients, as the NIH usually enrolls about 200 patients per week in clinical trials of experimental drugs.

Shutdown halts NIH drug trials as researchers hit brakes on preclinical research

The National Institutes of Health normally enrolls about 200 patients a week in ongoing trials of experimental therapies. Now, with about 73% of NIH staff sitting at home, the agency can't begin any new studies, forcing researchers to turn patients away.

UPDATED: Government shutdown halts NIH research, CDC disease surveillance

With Congress at an impasse over budget negotiations, the U.S. federal government on Tuesday halted operations deemed nonessential, bringing clinical trials, research of life-threatening diseases and disease-monitoring programs to a standstill.

NIH expands vaccine clinical trial network

Over their 50-year history, the National Institutes of Health's (NIH) Vaccine and Treatment Evaluation Units (VTEUs) have shaped immunization policy by stepping up when industry can't--or won't--run trials. This week, NIH reiterated its belief in the model by expanding its network.